



CNMV
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Vigo, June 28, 2018

Pursuant to article 228 of the restated text of the Securities Market Law, we hereby inform you of the following **SIGNIFICANT EVENT**:

The Ordinary General Shareholders' Meeting of Pharma Mar, S.A. at its meeting held today, on second call, approved by a sufficient majority of votes all the proposals that the Board of Directors had agreed to submit to its deliberation and decision.

The resolutions adopted correspond, therefore, with the proposed resolution that were communicated to that Commission through Significant Event number 266.065 on May 24, 2018 and which we summarize below:

1. Approval of the Annual Financial Statements and Management Report of Pharma Mar, S.A. and its Consolidated Group for fiscal year 2017, approval of the proposal for the allocation of losses in the amount of EUR 136,840,519.97 to increase the negative income statement balance from previous fiscal years and approve the management by the Board of Directors in that period.
2. Reappoint for a one-year period to Pricewaterhouse Coopers Auditores, S.L. as the Company's Statutory Auditor and its Consolidated Group.
3. To establish in ten (10) the effective number of members of the Board of Directors. To Appoint Mr. Valentín de Torres-Solanot del Pino as director of the Company for the statutory period of four years, with the qualification of Independent Director. To re-elect for the statutory period of four years, the following Directors: Mr. José María Fernández Sousa, with the qualification of Executive Director; Mr. Pedro Fernández Puentes, with the qualification of Executive Director; Rosp Corunna Participaciones Empresariales, S.L. (represented by Mr. José Leyte Verdejo), with the qualification of Proprietary Director; and Ms. Ana Palacio Vallelersundi as director of the Company for the statutory period of four (4) years, with the qualification of Independent Director.
4. Authorization to the Board of Directors, with express power of substitution, to buyback treasury stock of Pharma Mar, S.A. either directly or through Group companies, for a maximum period of 5 years from the date of the General Meeting, and that the par value of the shares acquired in aggregate with shares already held by the Company and its subsidiaries, does not exceed 10% of the subscribed capital.

Pharma Mar S.A.
Avda. de los Reyes, 1
P.I. La Mina
28770 Colmenar Viejo
(Madrid) Spain
www.pharmamar.com

5. Approval of a Free of Charge Stock Ownership Plan for fiscal year 2019 aimed at officers and employees of Pharma Mar Group who, having an indefinite contract and receiving variable compensation, meet more than 50% of their targets set for fiscal year 2018, up to a total maximum limit of 500,000 shares of Pharma Mar, S.A., to be delivered in implementation of this Plan.
6. Approval, on an advisory basis, the Annual Report on Compensation of Directors of Pharma Mar, S.A. for fiscal year 2017.
7. Approval, in accordance with the provisions of article 529 novodecies of the Spanish Capital Corporations Law, Pharma Mar, S.A.'s Directors' Compensation Policy for fiscal years 2019, 2020 and 2021.
8. Authorization to the Board of Directors to interpret, remedy, supplement, implement, execute and develop the resolutions adopted by the General Meeting, both to record such resolutions in a public deed and to substitute the powers entrusted thereto by the General Meeting.

The text of the resolutions adopted and the results of the voting will be published on the Company's website within the next five days.